Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Outlines Differentiated Profile of Its HSC Gene Therapy Approach and Discusses Potential Future Applications at Virtual R&D Investor Event
September 14, 2021 06:00 ET | Orchard Therapeutics (Europe) Limited
Novel Discovery Research in HSC-generated Antigen-specific Regulatory T Cells Disclosed HSC Gene Therapy Also Provides Advantages for Delivery of Monoclonal Antibodies New Applications Present...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Bolsters R&D and Technical Operations Leadership with New Executive Appointments
September 09, 2021 07:00 ET | Orchard Therapeutics (Europe) Limited
Gene therapy experts Fulvio Mavilio, Ph.D., and Nicoletta Loggia, Ph.D., join as chief scientific officer and chief technical officer, respectively Neuroscience and rare disease leader Leslie...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics to Host Virtual R&D Investor Event on Tuesday, September 14, 2021
September 08, 2021 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will webcast a virtual R&D Investor...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
September 07, 2021 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the Compensation Committee of Orchard’s Board of...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics to Present at Multiple Investor Conferences in September 2021
September 01, 2021 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present and be...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Business Updates
August 04, 2021 07:00 ET | Orchard Therapeutics (Europe) Limited
Regulatory feedback obtained on OTL-200 (MLD) and OTL-203 (MPS-IH) programs New HAE collaboration with Pharming Group highlights broad potential for HSC gene therapy Multiple...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo autologous HSC Gene Therapy for Hereditary Angioedema
July 01, 2021 01:00 ET | Orchard Therapeutics (Europe) Limited
Highlights the broader potential of Orchard’s ex vivo HSC gene therapy platform approach in new and larger indications Reinforces Pharming’s commitment to the HAE community and utilizes its relevant...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Announces Regulatory and Clinical Updates for Lead Gene Therapy Programs
June 29, 2021 07:00 ET | Orchard Therapeutics (Europe) Limited
Expected clinical package for OTL-200 BLA for MLD using data from existing patients clarified with FDA Guidance obtained on design of OTL-203 global registrational trial for MPS-IH Enrollment goal...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Reports First Quarter 2021 Financial Results and Provides Recent Business Updates
May 13, 2021 07:00 ET | Orchard Therapeutics (Europe) Limited
Commercial Activities Advancing for Upcoming Launch of LibmeldyTM (atidarsagene autotemcel) for Eligible Patients with Early-onset MLD in Germany Update on OTL-200 U.S. BLA Filing Strategy for...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Announces New England Journal of Medicine Publication of HSC Gene Therapy Data for ADA-SCID
May 11, 2021 06:00 ET | Orchard Therapeutics (Europe) Limited
100% overall survival and ≥95% event-free survival observed at two and three years following one-time treatment with lentiviral HSC gene therapy 50 total participants represent largest published...